OpenAI released GPT-Pro, a $200 model capable of extended reasoning over multi-day periods, demonstrated by solving previously unsolved mathematical problems. For healthcare AI, this capability directly addresses a critical gap in clinical decision support: the ability to reason through complex diagnostic scenarios, drug interaction pathways, and treatment protocol design that require sustained analytical depth beyond single-query responses. Extended reasoning windows could transform how AI assists in rare disease diagnosis, clinical trial design, and evidence synthesis for value-based care programs. However, the emerging pattern of experts becoming dependent on AI-assisted reasoning (per concurrent reporting) raises questions about healthcare professionals maintaining independent clinical judgment and validation skills. Healthcare organizations evaluating AI vendors should now assess extended reasoning capabilities as a core requirement alongside traditional safety and compliance benchmarks.